- Home
- ROIV vs NBIX Comparison
ROIV vs NBIX Comparison
Compare ROIV & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | NBIX |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 15.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ROIV | NBIX |
|---|---|---|
| Price | $21.33 | $136.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | $24.31 | ★ $177.19 |
| AVG Volume (30 Days) | ★ 8.3M | 971.4K |
| Earning Date | 02-09-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | N/A | ★ 4.19 |
| Revenue | $20,329,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | N/A | $23.68 |
| Revenue Next Year | $741.42 | $18.47 |
| P/E Ratio | ★ N/A | $33.54 |
| Revenue Growth | N/A | ★ 19.61 |
| 52 Week Low | $8.73 | $84.23 |
| 52 Week High | $23.47 | $160.18 |
Technical Indicators
Market Signals| Indicator | ROIV | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 33.18 |
| Support Level | $21.36 | $141.00 |
| Resistance Level | $22.21 | $148.56 |
| Average True Range (ATR) | 0.73 | 3.72 |
| MACD | -0.17 | -1.31 |
| Stochastic Oscillator | 19.30 | 12.66 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.